In the present study, we also found that the downregulation of ARID1A expression resulted in EMT in TNBC cells, suggesting that ARID1A plays a role in regulating EMT in breast cancer and could be a useful biomarker for identifying a subgroup of TNBC patients with poor prognosis and a potential target for preventing the metastasis of TNBC. This evidence concerns the gene ARID1A and breast carcinoma.